Orion and Criceto Will Change Parkinson's Disease Treatment with APORON®

Orion and Criceto Collaborate on APORON® for Parkinson’s Disease

Orion Corporation and Criceto IKM B.V. have come together to form a groundbreaking partnership aimed at the development and commercialization of APORON®, a novel apomorphine oromucosal spray. This medication is designed specifically for treating OFF episodes in patients suffering from Parkinson’s disease, a condition characterized by disabling motor fluctuations. Currently, APORON® finds itself in the critical Phase 3 development stage led by Criceto.

Understanding the License Agreement

The mutual agreement grants Orion an exclusive license to distribute Criceto’s proprietary apomorphine spray in various global markets, excluding only the United States and Canada. Patients dealing with OFF episodes often experience significant challenges that adversely affect their quality of life, making effective treatment essential.

The Importance of the Treatment

APORON® serves as a rescue therapy, offering on-the-spot relief for patients experiencing such episodes. The agreement between the companies includes provisions for upfront payments, cost reimbursements for ongoing development, and future royalties—establishing a solid financial framework for the collaboration.

A Commitment to Patient Care

Hao Pan, Executive Vice President of Branded Products at Orion, expressed enthusiasm about this venture, stating, "We are excited to enter this collaboration with Criceto. At Orion, we strive to improve the lives of patients living with Parkinson’s disease, aiming to provide treatment options for all stages and assist patients during their journey.”

Enhancing Parkinson’s Disease Management

Dr. Bert Tuk, Chief Executive Officer of Criceto, also highlighted the importance of the partnership: “This collaboration leverages Criceto’s expertise in developing advanced rescue treatments for Parkinson’s disease. We are proud to advance the APORON® project, which has the potential to be the leading rescue treatment for OFF episodes.”

About Criceto IKM B.V.

Criceto is an innovative, privately held pharmaceutical company dedicated to enhancing care for patients suffering from Parkinson’s disease. Their focus is specifically on creating and advancing treatment solutions like APORON®, which is currently making significant strides in its development, aiming to become the first choice for managing OFF episodes in patients.

About Orion Corporation

Orion has been a cornerstone in the pharmaceutical industry for over a century, providing well-being-driven solutions. This Nordic company excels in the development and marketing of both human and veterinary pharmaceuticals, alongside a varied portfolio that includes consumer health products. Orion’s R&D is robust, focusing on oncology and pain management, among other critical areas. Recently, Orion reported net sales reaching EUR 1,542 million, supporting a dedicated team of around 3,700 professionals committed to patient health. Their shares are traded on Nasdaq Helsinki under the ticker ORNBV.

Contact Information for Inquiries

For further information, you can reach out to:
Hao Pan
Executive Vice President, Branded Products
Tel: +44 16 3552 0300

Frequently Asked Questions

What is APORON®?

APORON® is an innovative apomorphine spray designed to provide treatment for OFF episodes in Parkinson’s disease patients.

What does the license agreement entail?

The license agreement allows Orion to exclusively market Criceto’s apomorphine spray globally, excluding the US and Canada.

What is the significance of the partnership?

This collaboration enhances treatment options for patients and aims to make a notable impact on the management of Parkinson’s disease.

Who can benefit from APORON®?

Patients experiencing OFF episodes associated with Parkinson’s disease can benefit from this new treatment option.

How is Orion involved in the pharmaceutical industry?

Orion is a longstanding pharmaceutical company developing a wide range of human and veterinary drugs, focusing on patient well-being for over a hundred years.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.